
David Planchard/oncostream.com
Jul 21, 2025, 17:01
David Planchard: FLAURA2 Regimen as a New Standart of Care for EGFRm NSCLC
David Planchard, Thoracic Oncologist, Professor at the University Paris Saclay and Head of the Thoracic Cancer Group at the Gustave Roussy, shared a post on X:
“What great news for our EGFRm NSCLC patients, with a survival benefit that confirms the FLAURA2 regimen (Osi + ChemoT) as a new standard of care 1st-line !
We look forward to seeing the final OS data…”
More post featuring David Planchard on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jul 21, 2025, 17:01
Jul 21, 2025, 17:00
Jul 21, 2025, 16:34
Jul 21, 2025, 16:26
Jul 21, 2025, 16:22
Jul 21, 2025, 16:04
Jul 21, 2025, 15:56
Jul 21, 2025, 15:50